

DISCLOSURES


- Research funding: Biogen Idec, Genentech/Hoffman-LaRoche, Shire/Takeda
- Advisory Board: Bayer, Genentech, Shire/Takeda, Sigilon, Uniqure
- Consulting: Aspa, I-mAb, Sunovion

Today's Agenda

- Case-based boards-based
- Thrombocytopenia
- Anemia
- RBC Transfusion Guidelines

60yo woman with DM and HTN admitted for dyspnea

- HPI: 4 days dyspnea, T 98.2F, BP 140/86, O2 sat 89% RA, breath sounds decreased at bases, +1 LE edema
- BNP 8320, trop T <0.01, creatinine 1.9
- CXR: Bilateral infiltrates (pulmonary edema)
- Echo: LVEF 55%, RV dysfunction
- V/Q scan: Mismatched perfusion defects consistent with bilateral PE




*What is the next step?

- A. Transfuse platelets
- B. Place IVC filter
- C. Stop heparin, start bivalirudin
- D. Catheter-directed thrombolysis
- E. Check a d-dimer


What is the next step?


- A. Transfuse platelets
- B. Place IVC filter
- C. Stop heparin, start bivalirudin
- D. Catheter-directed thrombolysis
- E. Check a d-dimer



Thrombocytopenia: Work-up


- Peripheral blood smear:
 - Pseudo-thrombocytopenia: Platelet clumping
 - Microangiopathic hemolytic anemia (MAHA): Schistocytes
 - Sepsis: Toxic granulation, vacuoles
- Myelophthisic (marrow invasion): Tear drops, left-shift • DIC panel
- PF4 (HIT) Ab
- HIV, hepatitis, EBV, CMV
- ANA, lupus anticoagulant
- Ultrasound: Spleen size





Possible \rightarrow 1 pt Definite \rightarrow 0

J Thromb Haemost 2006;4:759-65



Heparin-Induced Thrombocytopenia

- · Risk factors:
 - Heparin > enoxaparin
- Orthopedic > cardiac surgery > medical patients
 Diagnosis:
- 4-T score: Negative predictive value 99%
 Anti-PF4 Ab: sensitivity >97%, specificity 74-94%
 SRA: Sensitivity 95%, specificity 95%
- Risk of VTE continues for >1 month
- Anticoagulate 4-6 weeks if no clot
 Anticoagulate at least 3 months with clot
- Start warfarin after PLTs are stable or >150k

My 4 T's for Thrombocytopenia

- Thrombocytopenia:
- PLT <5: ITP, meds, bone marrow disorders (MDS, leukemia, aplastic anemia)
- PLT <50: TTP/HUS
- PLT 40-150: HIT, hypersplenism, infections
- Any PLT count: Meds
- Timing of decline:
- Acute: Meds, infection, HIT (5-10 days)
 Subacute: Leukemia, ITP
- Subacute: Leukem
 Chronic: MDS, ITP
- Thrombosis: HIT syndrome, APLS, malignancy, DIC, (ITP!)
- Other causes of thrombocytopenia: ITP vs. other

66yo woman with DM, HTN, pneumonia: Thrombocytopenia

- HPI: Fevers, malaise, and productive cough
- PMHx: DM, hypertension
- MEDS: Insulin, lisinopril
- Exam: Appears unwell, lethargic, T 101.4F, BP 70/30, HR 120, O2 sat 90% RA, crackles at left base, trace ankle edema
- IV fluids, norepinephrine gtt, cefotaxime, levofloxacin, and vancomycin, enoxaparin
- 3rd hospital day: Platelets fell from 340k to 90k
- WBC 11.3, HCT 34%, MCV 88, PLT 90k, PT 12.6, INR 1.0, PTT 32, fibrinogen 290, BUN 30, creat 1.2

*66yo woman with DM, HTN, pneumonia: Thrombocytopenia

- What is the most likely cause of her thrombocytopenia?
- A) HIT
- B) ITP
- C) DIC
- D) Drug-induced thrombocytopenia
- E) MDS

66yo woman with DM, HTN, pneumonia: Thrombocytopenia

- What is the most likely cause of her thrombocytopenia?
- A) HIT
- B) ITP
- C) DIC
- D) Drug-induced thrombocytopenia
- E) MDS

My 4 T's for Thrombocytopenia

Thrombocytopenia:

- PLT <5: ITP, meds, bone marrow disorders (MDS, leukemia, aplastic anemia)
- PLT <50: TTP/HUS
- PLT 40-150: HIT, hypersplenism, infections
- Any PLT count: Meds
- Timing of decline:
 - Acute: Meds, infection, HIT (5-10 days)
 - Subacute: Leukemia, ITP
 Chronic: MDS, ITP
- Thrombosis: HIT syndrome, APLS, malignancy, DIC, (ITP!)
- Other causes of thrombocytopenia: ITP vs. other

Drug-Induced Thrombocytopenia

- Suspect: Antibiotics especially...
 - TMP-SMX, penicillins, cephalosporins, vancomycin
 - Quinine, quinidine
 - Oxaliplatin, gemcitabine
 - Carbamazepine, phenytoin
 - Heparin
- Consider drug-specific platelet antibodies
- Onset: 1-2 weeks
- Recovery: Within 1 week (possibly up to 4 weeks)

36yo woman with no PMHx: Thrombocytopenia

- HPI: URI previous week, then developed rash
- PMHx: None
- MEDS: None
- Exam: Afebrile, 110/80, HR 80, O2 sat 98% RA, petechiae and ecchymoses
- WBC 7.6, HCT 38%, MCV 88, PLT 2k, PT 12.6, INR 1.0, PTT 32, fibrinogen 290, BUN 30, creat 1.2
- Smear: Confirms severe thrombocytopenia

*36yo woman with no PMHx: Thrombocytopenia

- WBC 7.6, HCT 38%, MCV 88, PLT 2k, PT 12.6, INR 1.0, PTT 32, fibrinogen 290
- What treatment should be tried first?
 - A) Dexamethasone
 - B) Prednisone
 - C) Rituximab
 - D) Plasmapheresis
 - E) Stem cell transplant

*36yo woman with no PMHx: Thrombocytopenia

- WBC 7.6, HCT 38%, MCV 88, PLT 2k, PT 12.6, INR 1.0, PTT 32, fibrinogen 290
- What treatment should be tried first?
 - A) Dexamethasone
 - B) Prednisone
 - C) Rituximab
 - D) Plasmapheresis

Dex 40mg PO x4d vs.

prednisone 1mg/kg

x4wks, then taper

n=192

- E) Stem cell transplant

ITP: Key Points

- Isolated thrombocytopenia: WBCs and RBCs are normal
- Diagnosis of exclusion
- WARNING: Wet purpura
- Chronic, relapses common
- Dexamethasone 40mg PO daily x4 days is standard of care

RCT: Dexamethasone better than prednisone

Response Rate:

82.1% vs 67.4%, P = .044

 CR (PLT >100k): 50.5% vs 26.8%, P = .001

Time to response:
 3d vs 6d, P < .001

Sustained response:

40.0% vs 41.2%, *P* = .884

Blood 2016;17:296-302

ITP: Treatment


- Steroids: Dexamethasone 40mg PO daily x4d
- IVIG
- Rituximab (anti-CD20 mAb): Targets B-cells
- TPO agonists: Romiplostim, eltrombopag, avatrombopag
- Splenectomy
- Fostamatinib: Syk inhibitor \rightarrow inhibits macrophage clearance
- Not necessarily in this order

	Anemia by MC۱	/
Ļ	Ļ	Ļ
Microcytic	Normocytic	Macrocytic
Iron deficiency	Anemia of CKD	Megaloblastic anemia
Thalassemia	Anemia of Inflammation	Alcohol/liver disease
Anemia of Inflammation	Acute blood loss	Reticulocytosis
Lead poisoning	Mixed	Meds: Hydroxurea, AZT MTX, TMP-SMX, phenytoin, valproate, azathioprine, imatinib
		MDS/AML, aplastic anemia

An	emia
Low Retic count & Normal Bili/LDH	High Retic count & Normal Bili/LDH
Hypoproliferative Anemia	Blood Loss
Low Retic count & High Bili/LDH	High Retic count & High Bili/LDH
Ineffective Erythropoiesis	Hemolytic Anemia

Anemia		
Low Retic count & Normal Bili/LDH	High Retic count & Normal Bili/LDH	
Hypoproliferative Anemia	Blood Loss	
Low Retic count & High Bili/LDH	High Retic count & High Bili/LDH	
Ineffective Erythropoiesis	Hemolytic Anemia	

etic count & Bili/LDH
oss
etic count <u>&</u> li/LDH
tic Anemia



Case: 32yo woman with fever and rash


- HPI: Fever started 3 days ago, she noticed a rash on her arms and legs today
- Exam: T 38.4C, mild scleral icterus, petechiae
- WBC 8.2, HCT 27, MCV 94, PLT 12
- PT, PTT, fibrinogen normal
- Retics 9%
- BUN 31, creat 1.4

Case: 32yo woman with fever and rash

- What is the most likely diagnosis?
 - A) Iron-deficiency anemia
 - B) ITP
 - C) Thrombotic microangiopathy (TMA)
 - D) Acute liver failure
 - E) Acute promyelocytic leukemia (APML)

*Case: 32yo woman with fever and rash

- · What is the most likely diagnosis? - A) Iron-deficiency anemia
 - B) ITP
 - C) Thrombotic microangiopathy (TMA)
 - D) Acute liver failure
 - E) Acute promyelocytic leukemia (APML)



TTP/HUS

The "Classic" Pentad:

- SCHISTOCYTES = MAHA (microangiopathic hemolytic anemia) THROMBOCYTOPENIA
- Neurologic abnormalities
- Acute kidney injury • Fever
- High LDH
- Normal coags

TTP: Treatment

TTP is uniformly fatal without plasmapheresis

NEJM 1991;325(6):393-7

TTP: Key Points

- Mobilize troops:
 - Examine smear for schistocytes
 - STAT page Hematology & Blood Bank for plasmapheresis
 - Dialysis-bore central line
 - Don't rest until pheresis starts!
- ADAMTS13 activity and inhibitor level PRIOR TO PHERESIS

Anemia

Low Retic count & Normal Bili/LDH	High Retic count & Normal Bili/LDH
Hypoproliferative Anemia	Blood Loss
Low Retic count & High Bili/LDH	High Retic count & High Bili/LDH
Ineffective Erythropoiesis	Hemolytic Anemia

Ineffective Erythropoiesis

- Erythropoiesis with early cell death
 - Can look like hemolysis, but without retics
- Etiology:
 - B12 and Folate Deficiency
 - MDS
 - Thalassemia


Case: 66yo man with dyspnea


- HPI: Exertional dyspnea worsening over 3 weeks, occasional lightheadedness
- PMHx: Osteoarthritis
- Meds: Naproxen, aspirin 81mg


LAB TEST	8 Months	Now
	Earlier	
WBC	6.3	8.1
RBC	4.8	2.4
Hb	13.2	7.5
НСТ	41%	22.5%
MCV	93	81
PLT	188	480
Retic count		1.1%
Creatinine		0.9


Case: 66yo man with dyspnea

- What is the most appropriate treatment for this patient?
 - A) EPO injection
 - B) Iron PO supplement
 - C) IV iron
 - D) pRBC transfusion
 - E) Hydroxyurea









STUDY	THRESHOLDS	N	OUTCOMES
ICU NEJM 1999	Restrictive: Hb <7 Liberal: Hb <10	838	No difference in 30-day mortality (restrictive better in less severe patients or age <55)
TRISS (Transfusion Requirements in Septic Shock) NEJM 2014	Restrictive: Hb <7-7.5 Liberal: Hb <10-10.5	1005	No difference in mortality and ischemic events
Severe acute upper GI bleeds NEJM 2013	Restrictive: Hb <7 Liberal: Hb <9	921	Restrictive: Reduced transfusions and adverse events and improved 6-week survival
TRIGGER: Severe acute upper GI bleeds Lancet 2015	Restrictive: Hb <8 Liberal: Hb <10	936	No differences in bleeding, thrombosis, ischemic events, infections, mortality, QUALY

RBC Transfusion In Cardiac Surgery: Controversy Laid to Rest

STUDY	THRESHOLDS	N	OUTCOMES
TRACS: Elective cardiac surgery JAMA 2010	Restrictive: HCT <24 Liberal: HCT <30	512	No difference in 30-day mortality and inpatient complications
TITRe2: Elective cardiac surgery NEJM 2015	Restrictive: Hb <7.5 Liberal: Hb <9	2007	No difference in 3-month ischemic events, infections, hospital LOS Liberal: 30-day mortality rate lower (1.9% vs. 2.6%) – secondary outcome
TRICS III: Moderate-high-risk cardiac surgery NEJM 2017 NEJM 2018	Restrictive: Hb <7.5 Liberal: Hb <8.5 (non-ICU) or <9.5 (ICU)	5243	No differences in 1-month and 6- month mortality, ischemic events, readmission, coronary revascularization – primary outcome

Summary: RBC Transfusions

- Many RCTs, meta-analyses, systematic reviews support **RESTRICTIVE RBC transfusion**:
- Transfuse if Hb <7-8
- Saves RBC Units and \$\$\$
- No difference in outcomes
- Unresolved questions in cancer surgery patients, elderly, and orthopedics

DISCLOSURES

- Research funding: Biogen Idec, Genentech/Hoffman-LaRoche, Shire/Takeda
- Advisory Board: Bayer, Genentech, Shire/Takeda, Sigilon, Uniqure
- Consulting: Aspa, I-mAb, Sunovion